Ozempic knockoffs could cost less than $3 per month: study
Source: SeekingAlpha
2026-03-06 08:17:19 ET
More on Novo Nordisk A/S
- Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
- Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable
- Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Ozempic knockoffs could cost less than $3 per month: study
Novo Nordisk A/S
NASDAQ: NVO
NVO Trading
0.69% G/L:
$38.88 Last:
4,716,867 Volume:
$38.73 Open:
NVO Latest News
March 09, 2026 12:44:07 pm
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
March 09, 2026 12:20:00 pm
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock
NVO Stock Data
$220,548,675,000
4,194,421,000
N/A
749
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
